What is Denali Therapeutics Inc.'s market cap?

Denali Therapeutics Inc. (DNLI) has a market capitalization of $3.7B and trades on NASDAQ.

Who are Denali Therapeutics Inc.'s competitors?

Denali Therapeutics Inc.'s key competitors include Alector, Inc., Eli Lilly and Company, Ultragenyx Pharmaceutical Inc., and others. These companies compete in similar markets and product categories.

Who does Denali Therapeutics Inc. partner with?

Denali Therapeutics Inc.'s notable partners include Biogen Inc., Takeda Pharmaceutical Company Limited, Sanofi S.A., and others.

What subsidiaries does Denali Therapeutics Inc. have?

Denali Therapeutics Inc.'s subsidiaries include Denali BBB Holding Limited.

Where is Denali Therapeutics Inc. headquartered?

Denali Therapeutics Inc. is headquartered in United States of America and employs approximately 375 people. It has been publicly traded since 2017.

Denali Therapeutics Inc.

DNLI

Denali Therapeutics is a clinical-stage biotechnology company focused on developing a broad portfolio of biotherapeutics for neurodegenerative and lysosomal storage diseases.

Market cap

$3.74B+88.4%

Net income-$508.0M-11.9%

Free cash flow-$419.2M-9.1%

EPS (diluted)-$2.88-7.5%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

EPS-$0.69Beat by $0.04

Read the full report

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$2.2M

EPS estimate-$0.54

Financials

Q1 2026

Income statement

See full

Operating income-$137.4M+5.6%

Net income-$128.4M+3.4%

EPS (diluted)-$0.69+11.5%

Balance sheet

See full

Cash & equivalents$390.7M+551%

Total debt$40.0M-22.3%

Total equity$926.1M-17.5%

Total assets$1.3B-0.4%

Cash flow

See full

Operating cash flow-$131.2M+0.2%

CapEx$2.5M-51.4%

Free cash flow-$133.7M+2.1%

Valuation & ratios

Valuation

See full

Market cap$3.74B+88.4%

Enterprise value$3.39B+80.0%

Returns & leverage

See full

Return on equity-49.6%+34.2pp

Debt / equity0×0.0×

Current ratio9.3×-0.3×

Segments

By product

See full

Milestone Triggered$25.0M0.0%

Milestone Payment$2.5M0.0%

Option Fee Payment$2.5M+100%

Competitors

By market cap

Eli Lilly$1.07T+47.2%

Regeneron Pharmaceuticals$69.9B+16.0%

Denali Therapeutics Inc.$3.7B+88.9%

Ultragenyx Pharmaceutical$2.6B+1.5%

uniQure$2.6B+220%

Atrium Therapeutics $197.9M-95.2%

Alector, Inc.$167.6M-4.7%

PAS

Passage Bio, Inc.$14.8M-32.5%

By revenue growth

Eli Lilly+47.4%

uniQure+30.2%

Ultragenyx Pharmaceutical+13.5%

Regeneron Pharmaceuticals+5.9%

By net margin

Eli Lilly34.99%+12.3pp

Regeneron Pharmaceuticals29.65%-2.3pp

Ultragenyx Pharmaceutical-90.92%+2.2pp

uniQure-1,350.73%+37.3pp

Denali Therapeutics Inc.-33,121.86%—

Profile

Denali Therapeutics is a clinical-stage biotechnology company focused on developing a broad portfolio of biotherapeutics for neurodegenerative and lysosomal storage diseases. The company leverages its proprietary Transport Vehicle (TV) technology platform to engineer large molecules, such as enzymes and antibodies, that can effectively cross the blood-brain barrier. Their core value proposition lies in transforming the treatment of central nervous system disorders by enabling systemic delivery of brain-penetrant medicines.

Competitive position

A leader in blood-brain barrier delivery technology with a proprietary platform that enables a modular approach to treating diverse CNS and systemic diseases.

GeographiesUnited States, European Union, China, Switzerland

Customer segmentsRare disease patients, Neurodegenerative disease patients, Pharmaceutical companies

Business modelR&D intensive, Licensing and Royalties, Collaborative Development

SuppliersContract Development and Manufacturing Organizations (CDMOs), Academic research institutions, Specialized laboratory equipment suppliers, Clinical trial site operators

CustomersSpecialty pharmacies, Hospitals and infusion centers, Biopharmaceutical collaboration partners, Government and private healthcare payers

CountryUnited States of America

Listed2017

Employees375.0

CEORyan J. Watts

SectorHealthcare

IndustryBiotechnology

Websitedenalitherapeutics.com

FilingsSEC EDGAR

Questions, answered.

What is Denali Therapeutics Inc.'s market cap?: Denali Therapeutics Inc. (DNLI) has a market capitalization of $3.7B and trades on NASDAQ.
Who are Denali Therapeutics Inc.'s competitors?: Denali Therapeutics Inc.'s key competitors include Alector, Inc., Eli Lilly and Company, Ultragenyx Pharmaceutical Inc., and others. These companies compete in similar markets and product categories.
Who does Denali Therapeutics Inc. partner with?: Denali Therapeutics Inc.'s notable partners include Biogen Inc., Takeda Pharmaceutical Company Limited, Sanofi S.A., and others.
What subsidiaries does Denali Therapeutics Inc. have?: Denali Therapeutics Inc.'s subsidiaries include Denali BBB Holding Limited.
Where is Denali Therapeutics Inc. headquartered?: Denali Therapeutics Inc. is headquartered in United States of America and employs approximately 375 people. It has been publicly traded since 2017.